TABRECTA

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Romania, Spain.

Active ingredients

The drug TABRECTA contains one active pharmaceutical ingredient (API):

1	Capmatinib UNII TY34L4F9OZ - CAPMATINIB
	Capmatinib is an inhibitor of the MET receptor tyrosine kinase. Capmatinib inhibits MET phosphorylation (both autophosphorylation and phosphorylation triggered by the ligand hepatocyte growth factor [HGF]), MET-mediated phosphorylation of downstream signalling proteins, as well as proliferation and survival of MET-dependent cancer cells.
	Read more about Capmatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TABRECTA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
TABRECTA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX17		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	526521080099201, 526521080099301
CA	Health Products and Food Branch	02527391, 02527405
ES	Centro de información online de medicamentos de la AEMPS	1221650002, 1221650004
FR	Base de données publique des médicaments	64594989, 66287227
HK	Department of Health Drug Office	66992, 66993
IL	מִשְׂרַד הַבְּרִיאוּת	9133, 9134
IT	Agenzia del Farmaco	050167016, 050167028, 050167030, 050167042
JP	医薬品医療機器総合機構	4291067F1023, 4291067F2020
LT	Valstybinė vaistų kontrolės tarnyba	1095017, 1095018, 1095019, 1095020
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69172001, W69173001
US	FDA, National Drug Code	0078-0709, 0078-0716